News

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

This new technology could one day significantly expand the market for gene-editing biotechs.

CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.

There's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

CRISPR Therapeutics stock has rebounded in the short term; however, over five years the share price is still significantly below where it was, while the current valuation checks lean toward the shares looking on the expensive side rather than clearly cheap. Over the past 5 years, CRISPR Therapeutics has delivered a return of about 58.5% in decline, which raises the question of whether the recent strength is a reset or just a pause in a longer weak spell. Investor attention around gene...

In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth, and Small Cap Comp Growth benchmarks. This broad index inclusion increases the company’s visibility to benchmarked funds and could meaningfully influence how investors view its role in growth-oriented portfolios. We’ll now examine how this broad Russell growth index inclusion shapes CRISPR Therapeutics’ investment narrative and...

The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD) who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT).

VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The ARK Innovation ETF (NYSEARCA:ARKK) has barely moved this year, gaining about 2% year to date through late June and sitting at roughly $78 per share. That stasis hides a violent tug of war inside the portfolio: AMD has more than doubled, up 144% YTD, while Coinbase has shed 34% and Tesla (NASDAQ:TSLA), ARKK’s largest ... Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move from the prior day.

The Healthcare Technology and Innovation index (HTEC) was launched back in 2019 with a specific purpose in mind: to allow investors to participate in the evolution of healthcare needed to address critical societal challenges. Issues such as an aging population, rising medical costs, and a shortage of skilled healthcare workers drove the creation of the [...]

The opportunity is enormous, but uncertainty remains.

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $53.09, indicating a +2.06% shift from the previous trading day.

They have at least one thing in common: An exciting pipeline.

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics (NasdaqGM:CRSP) filed a large shelf registration, creating capacity to issue new securities over time. Shareholders approved amendments to the articles of association, allowing for potential changes to capital structure and corporate governance. These moves give the company more flexibility for future financing, transactions, or operational shifts. CRISPR Therapeutics focuses on gene editing therapies, an area that has drawn attention as companies work on treatments for...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 27, research firm Citizens reiterated a Market Perform rating and a $60 price target on CRISPR Therapeutics AG (NASDAQ:CRSP). The stance comes on the heels of the company maintaining a positive view of in vivo editing […]

Eli Lilly reported positive Phase 1b data for VERVE-102, a gene-editing cardiovascular therapy, raising fresh competitive pressure on CRISPR Therapeutics' CTX310 program. CRISPR Therapeutics (NasdaqGM:CRSP) is broadening beyond gene editing with the acquisition of CTX611, a phase 2 siRNA therapy targeting blood clotting. These developments arrive as large pharma and specialist biotech companies increase focus on genetic and RNA-based approaches to cardiovascular disease. For you as an...

Its revolutionary CASGEVY treatment could be a sign of what's to come.

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Eli Lilly's pipeline is an embarrassment of riches.

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.